Our AI-powered Code-Breaker™ platform interrogates small RNAs (sRNAs) isoform hotspots that drive heterogenous diseases

CODE-BREAKER CHARACTERIZES THE LANDSCAPE OF FUNCTIONAL sRNA ISOFORMS, MODELS THEIR ROLE IN DISEASE, IDENTIFIES PATIENT SUBSETS, AND DIGITALLY DESIGNS PRECISION DRUGS IN < ONE YEAR

BIOLOGY-INFLUENCED MACHINE LEARNING IDENTIFIES HOTSPOTS WHERE THERE IS HIGH ISOFORM BURDEN SHARED BETWEEN GROUPS OF PATIENTS WITHIN A DISEASE INDICATION

Platform analyzes millions of sRNA features to identify mutations that :

  • Classifies disease
  • Stratifies subjects
  • Predicts disease drivers
  • Designs biomarker-guided precision oligonucleotide therapies

OLIGONUCLEOTIDES TARGETING THE EFFECTS OF DISEASE-DRIVING sRNA ISOFORMS REPRESENT A NEW CLASS OF RNA THERAPEUTICS

sRNA therapeutics are delivered using lipid nanoparticles (LNPs) and conjugates

High fidelity therapeutics targeting sRNA isoforms enable unmatched precision

Advancements in LNP and conjugate chemistry enable drug delivery to specific tissue

SEMANTIC KNOWLEDGE GRAPH DISCOVERS COMMON HOTSPOTS WHERE THERE IS HIGH ISOFORM BURDEN ACROSS DISEASE INDICATIONS

Disease Linkage

Discover novel drugs that treat multiple indications

Repurpose existing compounds including small molecules, protacs, MABs

Introduce new combinational therapies

Next: LEARN MORE ABOUT small RNAs (sRNAs)

Contact Us

Thanks for your interest! Please fill out the form below to download a copy of our case study

David Salzman, PhD

As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.


View his publication record here.

If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.